COPD

Multiple studies suggest that the mechanisms of lung damage and chronic obstructive pulmonary disease (COPD) due to biomass smoke differ from COPD caused by smoking cigarettes.

Patients with chronic obstructive pulmonary disease (COPD) are more likely to die in the year after undergoing surgery and rack up higher health care costs post-operation, study finds.

Medical experts provide their closing thoughts on the chronic obstructive pulmonary disease treatment landscape.

Cost drivers and payer considerations are emphasized for treatment of patients with chronic obstructive pulmonary disease.

Adding air purifiers into the home directly improves cardiac autonomic function and respiratory health for patients living with chronic obstructive pulmonary disease (COPD).

Nonmedication COPD strategies, such as pulmonary rehabilitation, are highlighted.

Selecting appropriate inhalers based on individual characteristics and shared decision-making is crucial for optimizing care for patients with COPD.

Despite chronic obstructive pulmonary disease (COPD) being associated with poor mental health and depression, most older adults report being free of mental illness or substance abuse, a new study has found.

Inhaler technique informs health care outcomes in COPD management and should be a primary focus in patient education priorities.

Treatment pathways, including escalation and de-escalation of therapy, for patients with COPD are explored by a panel of medical experts.

This year’s most-read articles on chronic obstructive pulmonary disease (COPD) includes researchon early interventions and possible health policy solutions.

Patient education is critical for self-monitoring of COPD disease progression.

An expert panel discusses appropriate transitions and adjustments to COPD treatment approaches.

New study findings call into question the necessity of spirometry as a criterion for participation in palliative care research among patients with chronic obstructive pulmonary disease (COPD).

Higher mortality rates linked with chronic obstructive pulmonary disease (COPD) are found in individuals employed in the mining and food service industries, according to a CDC analysis.

Key opinion leaders highlight the triple therapy approach from the most recent GOLD guidelines, including ICS, long-acting beta-agonist (LABA), and long-acting muscarinic antagonist (LAMA).

Inhaled corticosteroids (ICSs) are a key incorporation to COPD treatment strategies.

The role of combination therapy is explored for the treatment of COPD.

Social determinants of health (SDoH) can create major barriers for access to care.

The findings suggest that treatment with fluticasone furoate (FF)/umeclidinium (UMEC)/vilanterol (VI) led to improvements and had a similar safety profile to both FF/VI and UMEC/VI regardless of patient chronic mucus hypersecretion status at baseline.

Global health policy should consider the impact of breathlessness symptoms in adults when addressing increasing rates of obesity, according to a recent study.

Social and economic burdens affecting patients with COPD provide significant obstacles to optimizing care.

Jeffrey D. Dunn, PharmD, MBA, leads a panel discussion on disease and treatment landscapes for COPD.

A risk prediction model may offer insight in evaluating depression and anxiety in patients with chronic obstructive pulmonary disease (COPD).

Results from a study on bronchoscopic lung volume reduction and lung volume reduction surgery may aid medical professionals in selecting the best treatment for patients with emphysema.